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KIM-1 expression in kidney 
allograft biopsies: Improving the 
gold standard
S Abulezz1
Long-term outcomes of kidney allografts have shown only marginal 
improvement over the last three decades, despite the remarkable 
improvement in acute rejection and one-year graft survival. Novel 
biomarkers of tubular injury may prevent irreversible damage to the 
tubulointerstitial compartment and improve allograft survival.
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In kidney transplantation, the diagnosis of 
acute kidney injury (AKI) has depended 
on morphologic evaluation of the allograft 
biopsy as the gold standard. Unfortunately, 
histologic ﬁndings of tubular injury do not 
diﬀerentiate among its possible etiologies, 
nor do they correlate with severity of the 
injury or its prognosis. Even protocol 
biopsies have not succeeded in correlating 
histologic changes with allograft outcome. 
Interest in improving the diagnostic tools 
for the early detection, treatment, and 
prognosis of immune injury to the graft 
has resulted in several advances in recent 
years. Specifically, markers of immune 
activation in the peripheral blood such 
as soluble CD30 and urinary markers 
of immune injury such as perforin and 
granzyme B were found to correlate with 
acute rejection. Tissue expression of CD20 
or FOXP3 in allograft biopsies which 
appear histologically similar was found 
to correlate with response to treatment. If 
conﬁrmed in longitudinal and less selec-
tive kidney transplant populations, these 
markers may result in better management 
of the transplant patients.
A particular problem in kidney trans-
plantation is the need for biomarkers of 
immune and nonimmune injury at dif-
ferent time periods after transplantation 
(Figure 1). In the immediate perioperative 
period, days 0–30, there is a desperate need 
for a biomarker with the following char-
acteristics: (1) predicts the development 
of delayed graft function and its sever-
ity and prognosis at the donor stage; (2) 
indicates the course of the transplant after 
implantation in order to assist in the choice 
of induction and length of time when 
calcineurin inhibitors need to be avoided; 
(3) allows early detection of immune injury 
in order to guide the timing of the biopsy; 
(4) adds to the morphologic diagnosis 
by guiding type and length of immuno-
suppressive therapy; (5) allows early 
detection of drug toxicity and indication 
of its course after reduction or withdrawal. 
In the second time period, days 31–180, 
stabilization of graft function and gradual 
reduction of immunosuppression are 
expected. The characteristics of the desired 
biomarker at this stage include many of 
those outlined previously, with major 
emphasis on the early detection of immune 
activation and drug toxicity and the guid-
ing of biopsy and therapy. The third time 
period includes long-term follow-up after 
day 180. In addition to the previously men-
tioned characteristics, a biomarker that can 
detect early development of tubulointersti-
tial ﬁbrosis and its extent and progression 
is needed in the diagnosis, management, 
and development of newer therapies for 
chronic allograft nephropathy.
Evaluation of biomarkers of acute allo-
graft dysfunction of nonimmune etiology 
has not fared as well as markers of immune 
activation and injury. Kidney injury mol-
ecule-1 (KIM-1) is a recently discovered 
transmembrane type 1 epithelial cell protein 
with an extracellular domain that includes 
immunoglobulin and mucin domains.1 It 
is not detected in normal kidneys but is 
upregulated in renal proximal tubules after 
injury. If cleaved by metalloproteinases, its 
ectodomain can be measured in urine after 
acute tubular injury. Published studies on 
the utility of KIM-1 as a biomarker of acute 
tubular injury in kidney transplantation are 
limited. In a rat model, increased mRNA 
expression of KIM-1 correlated with neph-
rotoxicity induced by the combination of 
cyclosporine and sirolimus.2 In another rat 
model, KIM-1 mRNA and urinary KIM-
1 correlated with cyclosporine toxicity 
and improved with intervention.3 A small 
human cross-sectional study of KIM-1 
mRNA expression and urinary KIM-1 
protein measurement has recently been 
reported.4 KIM-1 mRNA expression was 
increased to a larger extent in acute than 
in chronic rejection, and urinary KIM-1 
correlated with immunohistochemical 
staining of the biopsies. Thus the transplan-
tation community welcomes the study by 
Zhang et al.5 (this issue) showing promis-
ing data on KIM-1 expression in kidney 
allograft biopsies. An important strength 
of this study is the availability of follow-up 
data 18 months after the biopsy. As was 
observed by the same group in ischemia/
reperfusion and nephrotoxic AKI, KIM-1 
staining correlated with the severity of the 
injury as measured by the deterioration 
in allograft function. KIM-1 staining also 
predicted prognosis in some transplant 
biopsies, as heavy staining correlated with 
improved kidney function at 18 months. 
Previous assumptions of the role of KIM-
1 in regeneration and diﬀerentiation of 
proximal tubular cells after injury were 
not borne out in biopsies with acute rejec-
tion, as no improvement in outcome was 
found to correlate with KIM-1 staining. As 
KIM-1 is not detectable in normal kidneys, 
its demonstration in 28% of protocol biop-
sies without histologic evidence of acute or 
chronic tubular injury could be interpreted 
as an improvement on the sensitivity of the 
allograft biopsy. In this group of protocol 
biopsies, there was no change in allograft 
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function or outcome at 18 months. With-
out the use of cutoﬀ values, this overlap in 
KIM-1 staining is likely to be problematic 
and may result in unnecessary biopsy if the 
test is the sole marker. The retrospective 
nature of this study, especially when the 
etiology of acute tubular injury is missing, 
does not allow scrutiny of the utility of the 
test in identifying drug-induced toxicity 
and its further management. Similarly, lack 
of information on the interventions under-
taken after the biopsies further undermines 
conﬁdence in the test’s ability to predict 
prognosis. Further evidence for the utility 
of this biomarker will need to come from 
a prospective study to test its validity in an 
unselected transplant population.
To date, there are few published stud-
ies of markers of acute tubular injury in 
kidney transplantation. Neutrophil gela-
tinase-associated lipocalin (NGAL) has 
been tested as a biomarker for delayed 
graft function. Staining for NGAL in 
biopsies obtained from deceased-donor 
kidneys correlated with the development 
of delayed graft function.6 Also, urinary 
NGAL and interleukin-18 predicted the 
development of delayed graft function 
with excellent sensitivity.7 Experimental 
proteomic analysis of urinary protein pro-
ﬁles has shown promise. Peaks in three dif-
ferent regions accurately identiﬁed patients 
with acute rejection and were not shared by 
transplant recipients suﬀering from acute 
tubular necrosis. Proteomic analysis could 
not discriminate between stable allografts 
with normal protocol biopsies and those 
with subclinical rejection.8
In summary, it should be obvious that 
no single biomarker has been identiﬁed to 
fulﬁll all the needs of a single stage in the 
course of kidney transplantation. Histologic 
evaluation of allograft biopsies remains the 
gold standard for the diagnosis of acute and 
chronic allograft dysfunction. At the same 
time, reliance on serum creatinine to time 
the biopsy, failure to detect subtle but con-
sequential signs of injury, and inability to 
predict prognosis and guide therapy have 
resulted in missed opportunities to aﬀect 
long-term graft survival. There are now 
available several promising biomarkers 
with acceptable predictive values in animal 
studies and limited cross-sectional human 
studies of kidney allografts. Advances in 
identifying biomarkers of AKI in the inten-
sive care unit and after cardiac surgery have 
been signiﬁcant. Only a few of these studies 
have included kidney transplant recipients, 
an ideal ﬁeld to test biomarkers of ischemia/
reperfusion, drug-induced nephrotoxicity, 
and other causes of AKI. Now is the time 
to validate the utility of these markers in 
large prospective trials that would study the 
performance of each biomarker alone and 
as part of a panel of markers for immune 
and nonimmune, acute and chronic injury. 
The close monitoring of kidney transplant 
recipients with frequent urinary and 
blood testing lends itself to testing of these 
biomarkers. In addition, the relative ease 
and lack of signiﬁcant complications have 
encouraged physicians to include protocol 
biopsies as part of patient management. 
These biopsies are prime testing sites for 
novel molecular targets.
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Figure 1 | Time periods after kidney transplantation and potentially useful biomarkers. 
Abbreviations: C4d, complement component 4d; CIT, cacineurin inhibitor toxicity; ELISPOT, enzyme-
linked immunosorbent assay; HLA, human leukocyte antigen; IL-18, interleukin-18; KIM-1, kidney 
injury molecule-1; NGAL, neutrophil gelatinase-associated lipocalin; PRA, panel-reactive antibody; 
sCD30, soluble CD30.
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